◀ All Modalities

Biologic Modality

Adipose-Derived
Mesenchymal Stem Cells

Mesenchymal stem cells harvested from subcutaneous adipose tissue via minimally invasive lipoaspirate. Among the highest MSC yield per unit volume of any adult tissue. Adipogenic, osteogenic, and chondrogenic differentiation capacity. Strong immunosuppressive paracrine profile. Autologous or allogeneic use.

Autologous Wound healing Joint pain Aesthetics Scar revision Anti-inflammatory High MSC yield
Request Information View Research
High
MSC yield vs bone marrow
3
Differentiation lineages
Low
Harvest morbidity
IRB
Largest in biologics

How it works

Mechanism of action

ADSCs work through paracrine signaling and direct differentiation. Their accessibility, yield, and immunomodulatory profile make them one of the most clinically versatile MSC sources available.

01
Minimally Invasive Harvest
ADSCs are isolated from subcutaneous adipose tissue obtained via lipoaspirate — a minimally invasive procedure. Adipose tissue yields significantly more MSCs per unit volume than bone marrow, with lower harvest morbidity. The stromal vascular fraction (SVF) is isolated through enzymatic digestion and centrifugation.
02
Paracrine Signaling
ADSCs release a rich secretome of growth factors (VEGF, TGF-β, FGF, HGF, IGF-1), cytokines, and exosomes that signal surrounding cells to reduce inflammation, proliferate, migrate, and repair. The paracrine mechanism is responsible for most of the therapeutic effect — not direct cell replacement.
03
Immunomodulation
ADSCs suppress pro-inflammatory T-cell activity and shift macrophages from the M1 inflammatory phenotype to the M2 repair phenotype. They also inhibit B-cell proliferation and NK-cell cytotoxicity — creating a systemic immunomodulatory effect that extends beyond the injection site.
04
Angiogenesis
VEGF secretion from ADSCs drives new blood vessel formation — critical for chronic wound healing where impaired vascularity is a primary barrier to recovery. ADSCs promote angiogenesis, fibroblast migration, and macrophage chemotaxis in wound healing models with consistently positive outcomes.
05
Chondrogenic Differentiation
Under appropriate stimulation (TGF-β, BMP-2), ADSCs differentiate into chondrocytes — enabling direct cartilage repair potential. Clinical trials show intra-articular ADSC injections reduce pain and improve function in knee OA with 87.5% of elderly patients maintaining or improving cartilage status at second-look arthroscopy.
06
Skin Regeneration & Anti-aging
ADSCs regulate skin regeneration through both paracrine signaling and direct differentiation into dermal cell types. They promote collagen synthesis, reduce scar formation, activate keratinocyte and fibroblast migration, and modulate aging-associated structural deficits — making them valuable in aesthetic and wound healing applications.

Where it works

Clinical Applications

ADSCs are among the most versatile MSC sources. Their accessible harvest site, high yield, and strong paracrine profile make them effective across wound healing, orthopedics, aesthetics, and dermatology.

🩹
Wound Healing
Chronic wounds · Diabetic ulcers · Exposed bone
 🧎
Joint Pain & OA
Knee OA · Cartilage repair · Pain reduction
 ✨
Aesthetics
Skin rejuvenation · Volume restoration · Anti-aging
 🏻
Scar Revision
Keloid · Hypertrophic · Atrophic scars
 🧖
Hair Restoration
ADSC-exo · AGA · Follicle stimulation
 ⚽
Sports Medicine
Soft tissue · Tendon · Ligament support
 🤰
Reproductive
Emerging applications · Tissue repair
 🧠
Neurological
Emerging · Neuroprotective paracrine

Evidence base

Peer-reviewed research on
Adipose-Derived MSCs

Selected from PubMed, PMC, and clinical trial registries. Covering wound healing, knee OA, scar revision, and comparative studies against BMAC.

Clinical trial
Intra-articular BMAC vs. ADSCs for knee osteoarthritis: prospective comparative clinical trial (102 patients)
Journal of Orthopaedic Surgery and Research · May 2023 · Pintore et al. · Both BMAC and ADSC injections showed significant improvement in pain and function at 6 months. KOOS, Oxford Knee Score, and VAS all improved significantly (p<0.0001) in both groups
 Systematic review
Safety and efficacy of autologous ADSCs for knee OA in elderly patients: systematic review
PMC · 2024 · 87.5% of elderly patients maintained or improved cartilage status at second-look arthroscopy. No total knee arthroplasty required during 2-year follow-up period
 Review
ADSC exosomes for osteoarthritis: anti-inflammatory and cartilage regeneration properties — bench to bedside analysis (2012-2024)
PMC · 2025 · Clinical trials demonstrate intra-articular ADSC injections safe and effective for pain relief and functional improvement, with higher doses showing superior outcomes
 Review
ADSC products and combination therapies for pathological scars: review of preclinical and clinical studies
PMC · 2025 · Comprehensive review of ADSC applications in keloid, hypertrophic, and atrophic scar treatment, including combination with CO2 laser and PRP
 Review
Adipose-derived stem cells in wound healing of full-thickness skin defects: a review of the literature
PubMed · 2020 · Most studies reported benefit and improvement in wound healing with all types of ADSC therapy. ADSC promotes angiogenesis, fibroblast migration, and macrophage chemotaxis
 Review
Hopes and limits of adipose-derived stem cells in wound healing: regulation of skin regeneration and aging-associated structural deficits
International Journal of Molecular Sciences · 2020 · Mazini et al. · ADSCs promote proliferation and differentiation into skin cells, activate cell regeneration through autocrine/paracrine pathways
 Clinical study
Autologous ADSC combined with high tibial osteotomy for knee OA: clinical outcomes correlated with stem cell stemness and senescence
Journal of Translational Medicine · Nov 2024 · ADSC combination therapy outcomes in knee OA — relationship between cell quality metrics and clinical results
 Review
Microfragmented adipose injections in the treatment of knee osteoarthritis: MSC presence in joints with duration of efficacy
PMC · 2019 · Koh et al. data showing improved cartilage whole organ MRI score and WOMAC pain scores after intra-articular ADSC injection in knee OA

Common questions

Questions about
Adipose-Derived MSCs

ADSCs are present in significantly higher numbers per unit volume of adipose tissue than MSCs in bone marrow. They proliferate more rapidly in culture, are less susceptible to senescence during expansion, and the harvest procedure is less invasive than iliac crest aspiration. Clinical studies comparing BMAC and ADSCs for knee OA showed comparable outcomes — both produced significant improvement in pain and function at 6 months — making ADSCs a viable alternative with lower harvest morbidity.
Adipose tissue is obtained via lipoaspirate — a minimally invasive procedure similar to a small-volume liposuction. Common harvest sites include the abdomen, flanks, or thighs. The harvested tissue is processed to isolate the stromal vascular fraction (SVF) containing MSCs, endothelial progenitors, and other regenerative cell types. Processing typically takes 1-2 hours, allowing same-visit injection in some protocols.
Multiple clinical studies support ADSC use in knee OA. A 2023 prospective comparative trial of 102 patients found both BMAC and ADSC injections produced significant improvement in KOOS scores, Oxford Knee Score, and VAS pain scores (p<0.0001 for both groups). A systematic review focused on elderly patients found 87.5% maintained or improved cartilage status at second-look arthroscopy, with no patients requiring total knee arthroplasty during the 2-year study period.
Yes. ADSC applications in facial aesthetics include skin rejuvenation, volume restoration, and anti-aging treatments. ADSCs are naturally positioned within the dermal layers and play a role in regulating skin regeneration and aging-associated structural changes. They promote collagen synthesis, activate fibroblasts, and reduce inflammatory responses associated with aging skin. ADSC-derived exosomes are also being investigated specifically for their hair restoration properties in androgenetic alopecia.

Get started

Ready to add adipose-derived
stem cells to your practice?

Give us 10 minutes. We’ll walk you through the protocols, the clinical evidence, and what this modality looks like for your specific specialty.

Contact Us Now Back to Home
Autologous · SVF Processed · IRB Protected
Important Regulatory Notice

Adipose-derived stem cell therapies are autologous biologics regulated under applicable FDA guidelines. Processing methods and clinical applications vary. ADSC therapies are not FDA approved as drugs for specific disease indications. Minimally manipulated autologous SVF used same-day is regulated under Section 361 HCT/P guidelines.

These therapies have not been evaluated by the FDA for safety or efficacy for every specific indication described. Results may vary. Clinicians are responsible for independent evaluation of suitability for each patient. This material is intended for licensed healthcare professionals only.

Our Biologics Distributors
© 2026 Our Biologics Distributors · Powered by Platinum Biologics, Orlando, FL.
Products are not FDA approved or licensed to treat, cure, or prevent any disease.